SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae
Open Access
- 10 January 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (1) , e0069523
Abstract
Carbapenem-resistant Enterobacteriaceae (CREs) are described by the Centers for Disease Control as an urgent threat, and there is a critical need for new therapeutic agents able to treat infections caused by these pathogens. Herein, we describe the microbiological profile, the mechanism f action, and the in vitro safety as well as the pharmacokinetic (PK)/PD profile of SMT-738, a small molecule belonging to a new chemical class. SMT-738 is active against Enterobacterales [including multi-drug-resistant Escherichia coli with 90% of isolates having a minimum inhibitory concentration (MIC 90 ) of 1 µg/mL and Klebsiella pneumoniae 2 µg/mL] and inactive against a broad panel of Gram-negative and Gram-positive pathogens. SMT-738 displays rapid bactericidal activity (2–4 h) and has a low propensity for resistance development (less than ~10 −9 ). Characterization of resistant mutants following exposure to SMT-738 identified mutations within the lipoprotein transport complex (LolCDE), a clinically unexploited and essential bacterial molecular target in Gram-negative bacteria. SMT-738 has a promising in vitro toxicology profile. Furthermore, PK studies demonstrated that when dosed intravenously, SMT-738 maintained exposure levels across infection sites (bloodstream/urinary tract/lung). Proof-of-concept studies across multiple murine in vivo infection models (bloodstream/pneumonia/urinary tract) demonstrated that SMT-738 significantly reduced the bacterial burden compared to baseline and vehicle control. SMT-738 represents a promising novel drug candidate being developed to address clinically challenging serious life-threatening infections caused by highly resistant Enterobacteriaceae including CRE.Keywords
This publication has 16 references indexed in Scilit:
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing EnterobacteriaceaeClinical Microbiology Reviews, 2018
- A Novel Inhibitor of the LolCDE ABC Transporter Essential for Lipoprotein Trafficking in Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2018
- A review on colistin nephrotoxicityEuropean Journal of Clinical Pharmacology, 2015
- A More Flexible Lipoprotein Sorting PathwayJournal of Bacteriology, 2015
- Small-Molecule Inhibitors of Gram-Negative Lipoprotein Trafficking Discovered by Phenotypic ScreeningJournal of Bacteriology, 2015
- The antibiotic alarmNature, 2013
- Membrane Topology and Functional Importance of the Periplasmic Region of ABC Transporter LolCDEBioscience, Biotechnology, and Biochemistry, 2009
- Lipoprotein trafficking in Escherichia coliArchives of Microbiology, 2004
- A new ABC transporter mediating the detachment of lipid-modified proteins from membranesNature Cell Biology, 2000
- Lethality of the covalent linkage between mislocalized major outer membrane lipoprotein and the peptidoglycan of Escherichia coliJournal of Bacteriology, 1997